Patents Assigned to Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
  • CYTOPROTECTIVE COMPOSITIONS FOR SHORT-TERM CELLS STORAGE AND TRANSPORTATION WITHOUT CRYOPRESERVATION AND DEEP FREEZING
    Publication number: 20230056314
    Abstract: A short-term storage of stem/progenitor cells in regenerative medicine without cryopreservation and cryoprotector. The protective composition of the invention improves the quality and increases the efficiency of cell therapy by keeping stem/progenitor cells free of ultra-low temperatures (liquid nitrogen) and cryoprotectants during the period of their biosafety testing and transportation to a patient’s bed.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 23, 2023
    Applicant: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Padma Priya Anand Baskaran, Sunil Pophale, Andrii Kukharchuk, Oleksandr Kukharchuk, Rohit Kulkarni
  • Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders and diseases
    Patent number: 11072776
    Abstract: A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: July 27, 2021
    Assignee: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Rohit Kulkarni, Sunil Pophale
  • FOETAL POLYMIX OF MESENCHYMAL STEM CELLS UNDER HYPOXIC CONDITIONS FOR THE TREATMENT OF CLINICAL DISORDERS AND DISEASES
    Publication number: 20210047614
    Abstract: A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Applicant: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Rohit Kulkarni, Sunil Pophale
  • Method of progenitor cell isolation from different organs by natural destruction of extracellular matrix
    Patent number: 10745664
    Abstract: The present invention is directed to novel methods comprising the isolation of viable fetal progenitor cells from organs of aborted fetus. The invention comprises the use of natural proteolytic, collagenolytic and fibrinolytic activity of autologous abortive placenta tissue extract.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 18, 2020
    Assignee: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Rohit Kulkarni, Sunil Pophale, Andrii Kukharchuk, Oleksandr Kukharchuk, Padma Priya Anand Baskaran